148 related articles for article (PubMed ID: 24751700)
1. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma.
Fujioka T; Toriihara A; Kubota K; Machida Y; Nakamura S; Kishimoto S; Ohashi I; Shibuya H
Nucl Med Commun; 2014 Aug; 35(8):857-63. PubMed ID: 24751700
[TBL] [Abstract][Full Text] [Related]
2. Preliminary study on the evaluation of olfactory neuroblastoma using PET/CT.
Wu HB; Wang QS; Zhong JM; Zhou WL; Li HS; Qiao-yu W
Clin Nucl Med; 2011 Oct; 36(10):894-8. PubMed ID: 21892040
[TBL] [Abstract][Full Text] [Related]
3. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.
Broski SM; Hunt CH; Johnson GB; Subramaniam RM; Peller PJ
J Nucl Med; 2012 Aug; 53(8):1200-6. PubMed ID: 22728262
[TBL] [Abstract][Full Text] [Related]
4. A case of olfactory neuroblastoma detected by (18)F-FDG PET/CT.
Tanaka K; Yamamoto Y; Hoshikawa H; Nishiyama Y
Clin Nucl Med; 2014 Jul; 39(7):635-6. PubMed ID: 24662664
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
6. Performance of (18)F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients.
Lee DY; Lee CH; Seo MJ; Lee SH; Ryu JS; Lee JJ
Ann Nucl Med; 2014 Oct; 28(8):789-95. PubMed ID: 24965850
[TBL] [Abstract][Full Text] [Related]
7. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
9. Performance of whole-body
Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061
[TBL] [Abstract][Full Text] [Related]
10. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
[TBL] [Abstract][Full Text] [Related]
13. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
14. Role of
Elkhatib AH; Soldatova L; Carrau RL; Hachem RA; Ditzel L; Campbell R; Prevedello DM; Prevedello L; Filho LF; Campbell RG
Laryngoscope; 2017 Feb; 127(2):321-324. PubMed ID: 27481043
[TBL] [Abstract][Full Text] [Related]
15. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-DOTATATE and 18F-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival Region.
Dadgar H; Norouzbeigi N; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2020 Aug; 45(8):e363-e364. PubMed ID: 32558717
[TBL] [Abstract][Full Text] [Related]
17. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
18. Can (18)F-FDG PET/CT reliably assess response to primary treatment of head and neck cancer?
Ul-Hassan F; Simo R; Guerrero-Urbano T; Oakley R; Jeannon JP; Cook GJ
Clin Nucl Med; 2013 Apr; 38(4):263-5. PubMed ID: 23429398
[TBL] [Abstract][Full Text] [Related]
19. (18)F-FDG PET in small-cell cervical cancer: a prospective study with long-term follow-up.
Chen MY; Chou HH; Liu FY; Chen CY; Lin G; Yang LY; Pan YB; Jung SM; Wu RC; Huang YT; Tsai JC; Yen TC; Lai CH; Chang TC
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):663-74. PubMed ID: 26519293
[TBL] [Abstract][Full Text] [Related]
20. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
